Haloperidol Grindeks (Haloperidol)

Haloperidol Grindeks is indicated for several psychiatric disorders where dopamine blockade is therapeutic. It is commonly prescribed in the following situations:

• Management of schizophrenia, including maintenance therapy.
• Treatment of acute psychotic episodes, such as agitation or severe hallucinations.
• Control of motor and vocal tics associated with Tourette syndrome.
• Short‑term sedation in emergency settings when rapid tranquilization is required.
• Adjunctive therapy for other conditions as determined by a qualified clinician.

Side effects of haloperidol can vary in frequency and severity. Patients should be informed about both common and serious reactions.

Common

• Drowsiness or sedation
• Extrapyramidal symptoms such as tremor or rigidity
• Dry mouth and increased salivation
• Constipation or gastrointestinal discomfort
• Blurred vision or ocular disturbances
• Weight gain or changes in appetite

Serious

• Neuroleptic malignant syndrome (fever, muscle rigidity, autonomic instability)
• Tardive dyskinesia (involuntary movements of face or limbs)
• Severe hypotension or cardiac arrhythmias
• Elevated prolactin levels leading to hormonal disturbances
• Agranulocytosis or severe leukopenia
• Seizures or worsening of pre‑existing seizure disorders

Haloperidol Grindeks should be used with caution and under professional guidance. Important safety considerations include:

• Assess cardiovascular status before initiating therapy, especially in patients with known heart disease.
• Monitor for signs of extrapyramidal reactions, particularly during dose escalation.
• Evaluate liver and kidney function periodically, as impairment may affect drug clearance.
• Use the lowest effective dose for the shortest duration needed to control symptoms.
• Discuss pregnancy, lactation, and potential effects on fetal development with a healthcare provider.
• Educate patients and caregivers about the risk of neuroleptic malignant syndrome and when to seek urgent care.

Haloperidol may interact with several other medications, altering its efficacy or safety profile.

Avoid

• Other dopamine antagonists or antipsychotics that may increase extrapyramidal risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels.
• Medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.

Use with caution

• CNS depressants (e.g., benzodiazepines, opioids) which may enhance sedation.
• Anticholinergic agents that can mask early signs of extrapyramidal symptoms.
• Lithium, due to potential additive neurotoxic effects.
• Antihypertensive drugs, as haloperidol can cause orthostatic hypotension.
• CYP2D6 substrates, since haloperidol is partially metabolized by this pathway.